Takita H
Department of Thoracic Surgery and Oncology, Roswell Park Cancer Institute, New York State Department of Health, Buffalo 14263, USA.
J Surg Oncol. 1996 May;62(1):65-74. doi: 10.1002/(SICI)1096-9098(199605)62:1<65::AID-JSO14>3.0.CO;2-S.
Surgical therapy remains the treatment of choice for resectable nonsmall-cell lung cancer (NSCLC). However, the 5-year survival results of surgical therapy is 40-70%, which is far from acceptable. In this report, past results of perioperative therapies were reviewed to identify the future direction of effort in improving the therapy of NSCLC. Two perioperative modes of treatment that may possibly improve postsurgical survival were identified, i.e., neoadjuvant chemotherapy for resectable NSCLC and postoperative specific active immunotherapy.
手术治疗仍然是可切除非小细胞肺癌（NSCLC）的首选治疗方法。然而，手术治疗的5年生存率为40%-70%，这远远不能令人接受。在本报告中，回顾了围手术期治疗的既往结果，以确定改善NSCLC治疗的未来努力方向。确定了两种可能提高术后生存率的围手术期治疗模式，即可切除NSCLC的新辅助化疗和术后特异性主动免疫治疗。
